If over-priced Xtandi is losing money now letting Zytiga eat its lunch, wait till 4 new drugs hit the market and Zytiga goes off patent in Feb. 2014.
JNJ has priced Zytiga lower than MDVN to get the lion's share of insurance coverage. Perfect.
Zytiga starts to go off patent in Feb. 2014, so JNJ is planning a generic version as well.
JNJ owns the improved versioin of MDVN's Xtandi and its inventor works for JNJ now. It is called ARN509 and it is safer, less side effects and more efficient than Xtandi. Phase 3 should be approved next year and ARN 810 just passed phase 1 for breast cancer.